Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 57 peer-reviewed journal articles Updated

Building Your Foundation: Understanding AAV

At a Glance

ANCA-associated vasculitis (AAV) is a rare but highly treatable autoimmune condition where the immune system attacks small blood vessels. The primary goal of treatment is remission, achieved through a two-phase approach of intensive induction therapy followed by long-term maintenance.

Receiving a diagnosis of ANCA-associated vasculitis (AAV) can feel like a sudden storm. It is a rare condition, and the terms used to describe it can be intimidating. However, understanding the basics of this disease and the road ahead is the first step in taking back control. AAV is an autoimmune condition, which means your immune system—which normally protects you—accidentally attacks the walls of your small blood vessels [1][2]. This causes vasculitis (inflammation of the blood vessels), which can limit blood flow to various organs [3].

While this is a serious condition, it is also highly treatable. Modern medicine has transformed AAV from a mysterious illness into a manageable chronic condition [4].

Three Stabilizing Facts

If you are currently feeling overwhelmed, keep these three foundational facts in mind:

  1. Remission is the Goal and it is Achievable: The vast majority of patients reach remission, a state where the disease is no longer active and symptoms fade [5][6].
  2. Modern Treatments are Highly Effective: Innovative therapies, such as rituximab and newer “steroid-sparing” drugs like avacopan, have significantly improved outcomes and safety compared to treatments used in the past [4][7].
  3. Some Lost Function Can Be Restored: While established tissue scarring or permanent nerve damage cannot be reversed, aggressive treatment in the early stages can halt active inflammation and lead to significant recovery of organ function [8][9].

Your Path Forward: The Two Phases of Care

The treatment for AAV is not a single event, but a journey divided into two clear stages. Think of it as putting out a fire and then making sure the embers don’t reignite [10].

  • Phase 1: Induction: This is the most intensive phase. The goal is to rapidly stop the inflammation and prevent organ damage [11]. It usually lasts for the first 3 to 6 months [10].
  • Phase 2: Maintenance: Once you are in remission, your doctors will switch your focus to staying there. This phase uses milder medications to keep the immune system in check [12][6].

Navigating This Guide

To help you understand your diagnosis, advocate for the best care, and prepare for your future, we have broken down the journey into four detailed sections:

01

The Biology of AAV: Why Your Body Attacks Itself

Learn the biology of ANCA-associated vasculitis (AAV). Understand how the immune system mistakenly attacks blood vessels, AAV subtypes, and PR3 vs. MPO tests.

02

Symptoms, Lab Results, and the Road to Diagnosis

Learn how ANCA-associated vasculitis (AAV) is diagnosed. Understand AAV symptoms, PR3 and MPO ANCA tests, biopsy results, and classification criteria.

03

The Roadmap of AAV Treatment: From Induction to Maintenance

Learn about the two phases of AAV treatment: induction to achieve remission and maintenance to prevent relapse. Understand your medication options and risks.

04

Living with AAV: Monitoring and Your Future Health

Learn how to navigate AAV remission and survivorship. Understand relapse signs, routine lab monitoring, managing steroid side effects, and when to seek care.

Validating Your Experience

It is completely normal to feel a heavy emotional weight after this diagnosis. Dealing with a rare disease requires a unique kind of resilience. You are learning a new medical language while managing physical symptoms and the stress of specialized treatments. While the journey through the initial phase can be challenging, remember that the medical focus has shifted from just “surviving” to ensuring you have a high quality of life and a functional, active future [13][14]. You are not alone, and your care team is equipped with more tools today than ever before.

Common questions in this guide

What is ANCA-associated vasculitis (AAV)?
AAV is a rare autoimmune condition where your immune system mistakenly attacks the walls of your small blood vessels. This causes inflammation, known as vasculitis, which can restrict blood flow to your organs and cause damage if left untreated.
Can AAV be cured or put into remission?
While AAV is a serious chronic condition, the vast majority of patients achieve remission. Modern treatments are highly effective at stopping active inflammation, managing symptoms, and preventing further organ damage.
What are the phases of AAV treatment?
Treatment usually involves two phases. The induction phase lasts 3 to 6 months and aggressively stops active inflammation. Once remission is reached, you will transition to the maintenance phase, which uses milder medications to keep the disease in check long-term.
What types of medications are used to treat AAV?
Treatment involves therapies to calm the immune system. Doctors commonly use medications like rituximab as well as newer, steroid-sparing drugs such as avacopan to achieve and maintain remission safely.
Will my organs recover from AAV damage?
Aggressive early treatment can halt active inflammation and restore significant organ function. However, established tissue scarring or permanent nerve damage that has already occurred usually cannot be reversed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my initial test results, do I have GPA, MPA, or EGPA?
  2. 2.Which of my organs are currently affected, and what tests will we use to track my progress?
  3. 3.What are the 'remission' goals for my specific case?
  4. 4.How can I best reach you or your team if I have a question between appointments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome.

    Fouka E, Drakopanagiotakis F, Steiropoulos P

    International journal of molecular sciences 2024; (25(10)) doi:10.3390/ijms25105278.

    PMID: 38791316
  2. 2

    Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

    Molnár A, Studinger P, Ledó N

    Frontiers in medicine 2022; (9()):884188 doi:10.3389/fmed.2022.884188.

    PMID: 35721093
  3. 3

    2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Chung SA, Langford CA, Maz M, et al.

    Arthritis care & research 2021; (73(8)):1088-1105 doi:10.1002/acr.24634.

    PMID: 34235880
  4. 4

    Comparison of Rituximab and Cyclophosphamide for Induction Therapy in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review of Randomized Trials and Comparative Cohort Evidence.

    Khan SH, Manzoor MZ, Khan J

    Cureus 2025; (17(12)):e99868 doi:10.7759/cureus.99868.

    PMID: 41573449
  5. 5

    Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

    Wechsler ME, Akuthota P, Jayne D, et al.

    The New England journal of medicine 2017; (376(20)):1921-1932 doi:10.1056/NEJMoa1702079.

    PMID: 28514601
  6. 6

    EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

    Yates M, Watts RA, Bajema IM, et al.

    Annals of the rheumatic diseases 2016; (75(9)):1583-94 doi:10.1136/annrheumdis-2016-209133.

    PMID: 27338776
  7. 7

    Avacopan for the Treatment of ANCA-Associated Vasculitis.

    Jayne DRW, Merkel PA, Schall TJ, et al.

    The New England journal of medicine 2021; (384(7)):599-609 doi:10.1056/NEJMoa2023386.

    PMID: 33596356
  8. 8

    Granulomatosis With Polyangiitis: A Clinical Case.

    Rodrigues F, Oliveira Sá AI, Mendes M, et al.

    Cureus 2022; (14(12)):e32410 doi:10.7759/cureus.32410.

    PMID: 36636531
  9. 9

    A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature.

    Lau RA, Bains R, Suraweera D, et al.

    Case reports in rheumatology 2017; (2017()):2421760 doi:10.1155/2017/2421760.

    PMID: 28348913
  10. 10

    [Granulomatosis with polyangiitis: what's new?]

    Ringwald M, Chevalley D, Bongard C, et al.

    Revue medicale suisse 2023; (19(821)):674-679 doi:10.53738/REVMED.2023.19.821.674.

    PMID: 37017349
  11. 11

    Practical Management of ANCA-Associated Vasculitis: A Clinician's Perspective.

    Stacey HL, Francis L, Smith RM, Jones RB

    Glomerular diseases 2025; (5(1)):84-102 doi:10.1159/000543159.

    PMID: 39991192
  12. 12

    How We Treat ANCA-Associated Vasculitis: A Focus on the Maintenance Therapy.

    Roccatello D, Fenoglio R, De Simone E, Sciascia S

    Journal of clinical medicine 2025; (14(1)) doi:10.3390/jcm14010208.

    PMID: 39797292
  13. 13

    Diagnosis and management of ANCA-associated vasculitis.

    Kronbichler A, Bajema IM, Bruchfeld A, et al.

    Lancet (London, England) 2024; (403(10427)):683-698 doi:10.1016/S0140-6736(23)01736-1.

    PMID: 38368016
  14. 14

    Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis.

    Sagy I, Jayne DRW

    Annals of the rheumatic diseases 2025; doi:10.1016/j.ard.2025.11.024.

    PMID: 41469274

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or specialist about your specific AAV diagnosis and treatment plan.

Get notified when new evidence is published on Anti-neutrophil cytoplasmic antibody-associated vasculitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.